검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Mometasone furoate nasal spray |
Overview Company | Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Nasal Polyps |
Overview Indication | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling |
MoA Biomarker | biomarkers were assessed |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.. Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [I… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 7.84% |
Clinical ORR | 1.63% |
Clinical Result source | ClinicalTrials.gov NCT00783224 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Mometasone furoate nasal spray |
Overview Company | Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Nasal Polyps |
Overview Indication | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling |
MoA Biomarker | biomarkers were assessed |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.. Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [I… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 7.84% |
Clinical ORR | 1.63% |
Clinical Result source | ClinicalTrials.gov NCT00783224 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교